Neuphoria Therapeutics Inc.’s phase III study of social anxiety disorder has missed its primary and secondary endpoints, prompting the company to stop the program’s development and hold a full strategic review of its operations and portfolio. It’s the second stumble for lead candidate BNC-210, a negative allosteric modulator of alpha7 nicotinic acetylcholine receptor, in the indication. Read More
Detailed Viktoria-1 results of Celcuity Inc.’s gedatolisib positions the pan-PI3K/mTORC1/2 inhibitor as a top contender for second-line treatment of HR+/HER2- PIK3CA wild-type advanced breast cancer – a multibillion-dollar indication in need of new treatments. Read More
Antibody-drug conjugates (ADCs) are a mature technology. The first ADC, Mylotarg, was initially approved in 2000, and there are now 14 approved agents in both leukemias and solid tumors. According to Clarivate’s Cortellis Drug Discovery & Intelligence, those drugs collectively accounted for $13.55 billion in sales in 2024 – a figure that Cortellis projects will rise to $16 billion in 2025. Read More
Step Pharma is financed to move its pipeline-in-a-product strategy forward on a broad front, after raising a €38 million (US$44.2 million) series C. That will see three ongoing trials testing the company’s potentially first-in-class, orally available cytidine triphosphate synthase 1 inhibitor, dencatistat, through to phase II in T-cell and B-cell lymphoma, in an ovarian, endometrial and lung cancer study, and in essential thrombocythemia. Read More
Samsung Bioepis Co. Ltd. announced Oct. 21 the signing of a license deal to codevelop, manufacture and commercialize two of Phrontline Biopharma Suzhou Co. Ltd.’s novel bispecific dual-payload antibody-drug conjugate (ADC) candidates. Read More
Radiopharm Theranostics Ltd. completed a AU$35 million (US$22.77 million) placement to advance six of its radiopharmaceutical candidates for both diagnostic and therapeutic uses. The funds raised will go toward clinical trials, drug manufacturing and working capital to extend Radiopharm’s funding runway into 2027. Read More
While positive results from the investigator-led phase II CHOPIN trial at ESMO 2025 failed to get investors dancing, they were no doubt music to management’s ears, particularly with Delcath Systems Inc.’s third quarter earnings report missing a beat. Read More
SK Biopharmaceuticals Co. Ltd. and Eurofarma Laboratórios SA launched a new joint venture called Mentis Care Inc. Oct. 21, dedicated to developing an AI-powered platform for epilepsy management. Read More
From Dolly the sheep to mRNA vaccines, BioWorld has been reporting every breakthrough and challenge along the way. Our commitment to accurate, contextualized journalism has helped readers navigate this fast-evolving industry for 35 years. Join us as we celebrate the milestones that shaped biopharma and medtech, then and now. Read More
Clinical updates, including data readouts and publications: Aicuris, Aurion, Corbus, Corcept, Exelixis, Genmab, IO, ITM, Leap, Merck, Olema Oncology, Roche, Sanofi, Vivace. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Contera, Cumberland Pharma, H. Lundbeck, Lava, Redhill, Xoma Royalty. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Amgen, Astrazeneca, Cogent, Glaukos, Novo Nordisk, Replimune, Salvat, Sanofi, Silver Creek, Xbrane. Read More
